# DESCRIPTION

- incorporate prior applications by reference

## TECHNICAL FIELD

- introduce peptidomimetics for HER2-overexpressed cancers

## BACKGROUND ART

- motivate EGFRs in human cancers
- describe EGFR signaling and dysregulation
- discuss limitations of existing cancer therapies
- summarize prior art on peptidomimetics for HER2
- highlight need for improved HER2-overexpressed cancer treatments

## SUMMARY OF THE INVENTION

- introduce novel peptidomimetics for HER2-overexpressed cancers
- describe peptidomimetic binding to HER2 and inhibition of dimerization
- highlight advantages of peptidomimetics over antibodies and peptides
- outline embodiments and applications of peptidomimetics

## MODES FOR CARRYING OUT THE INVENTION

- illustrate compound structure
- describe variations of compound
- specify synthesis methods
- show backbone modifications

### Definitions/General Discussion

- define scope of invention
- clarify terminology usage
- specify statutory class of invention
- describe method claim interpretation
- define nomenclature for compounds
- specify singular and plural forms
- define ranges and approximations
- describe parts by weight in compositions
- define weight percent in formulations
- clarify optional components
- define subject and patient
- describe treatment and prevention
- define administering and administration
- specify contacting and effective amounts
- describe EC50 and IC50
- define pharmaceutically acceptable
- clarify derivatives and leaving groups
- define cycloalkyl
- define heterocycloalkyl
- define polyalkylene group
- define alkoxy
- define alkenyl
- define cycloalkenyl
- define alkynyl
- define cycloalkynyl
- define aryl
- define various functional groups
- define silyl
- define sulfo-oxo
- define sulfonyl
- define sulfone
- define sulfoxide
- define thiol
- describe R groups
- describe optionally substituted moieties
- define stable
- list monovalent substituents on a substitutable carbon atom
- list divalent substituents on a saturated carbon atom
- describe substituents on R*
- describe substituents on a substitutable nitrogen
- describe substituents on Râ€ 
- define organic residue
- define radical
- describe inorganic radicals
- discuss isomers
- define diastereomers and enantiomers
- describe isotopically-labeled compounds
- discuss solvates and hydrates
- define co-crystals
- discuss polymorphic forms
- describe commercially available materials
- discuss methods of making and using compositions
- describe structural features and functions
- discuss derivatives and modifications
- describe physical properties and stability
- discuss substantially pure compounds and mixtures
- describe synthetic methods and products
- discuss pharmaceutical compositions and manufacturing
- describe methods of administration and dosage forms
- discuss oral administration and formulations
- describe non-oral routes of administration
- discuss effective doses and combination therapy
- provide examples of dosages and administration frequencies
- discuss scope and modifications of the invention

### Example 1. Compound 18: Synthesis and Characterization

- synthesize compound 18 using solid phase Fmoc chemistry
- characterize compound 18 by LC-MS and 1H 2D-NMR
- determine stereochemistry of compound 18

### Example 2. Inhibition Testing

- evaluate antiproliferative activity of compound 18 against various cancer cell lines

### Table 3 Notes:

- describe experimental conditions for antiproliferative activity testing

### Example 3. Competitive Binding Assays

- confirm binding of compound 18 to HER2 domain IV using competitive binding assay

### Example 4. Testing Compound 18 Analogs for PPI Inhibition

- evaluate antiproliferative activity of compound 18 analogs against various cancer cell lines

### Notes to Tables 4 and 5:

- describe experimental conditions for antiproliferative activity testing of compound 18 analogs

### Example 5. Dose-Response Curves for Heterodimerization

- inhibit HER2-HER3 heterodimerization with compound 18
- measure dose-response curve for heterodimer inhibition by compound 18
- compare dose-response curves for compound 18 and control compound
- depict dose-response curve for heterodimer inhibition by compound 18
- depict dose-response curve for heterodimer formation by Neuregulin-1
- depict effect of control compound on heterodimer formation
- conduct Western blot analysis of HER2 protein in BT-474 cells
- inhibit phosphorylation of HER2 kinase domain with compound 18
- study inhibition of PPI in HER2-overexpressing cancer cell line SKBR-3
- use proximity ligation assay to detect HER2-HER3 PPI
- observe decrease in red fluorescence dots with compound 18
- conduct Western blot analysis of phosphorylated HER2 protein in Calu-3 lung cancer cells
- inhibit phosphorylation of HER2 protein with compound 18
- use glyceraldehyde 3-phosphate dehydrogenase as loading control
- detect phosphorylation using p-HER2 antibody

